Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Fecal Microbiota Transplantation (FMT) to Slow Biological Aging (LONGEVIBIOME)

30. oktober 2026 oppdatert av: Human Biome S.A.

A Randomized, Double-blind, Placebo-controlled Research Study Evaluating the Efficacy and Safety of Multi-dose Fecal Microbiota Transplantation (FMT) in Capsule Form as an Intervention to Slow Down the Rate of Biological Aging.

The goal of this clinical trial is to evaluate if multi-dose fecal microbiota transplantation (FMT) capsules can safely and effectively slow down biological aging and reduce chronic low-grade inflammation in adults aged 45 to 80 with metabolic neglect.

The main questions it aims to answer are:

  • Can oral FMT capsules significantly slow the biological pace of aging as measured by the DunedinPACE epigenetic clock?
  • Can FMT successfully reduce chronic systemic inflammation (measured by markers such as suPAR, IL-6, and hs-CRP)?

Researchers will compare participants receiving the active product to those receiving a matching placebo to see if the microbiome intervention improves metabolic health and cognitive function via the gut-brain axis.

Participants will:

  • Undergo a short-term preparation phase involving targeted antibiotics and standard bowel cleansing.
  • Receive an 2 initial induction doses of active product (or placebo) followed by 5 regular booster cycles administered approximately every 4 weeks.
  • Attend periodic clinical visits for physical examinations, blood draws, stool sample collection (at home), and cognitive testing using the CANTAB platform and MoCA scale.
  • Maintain a participant diary to record adverse events (AE), product administration, stool sample collection, and dietary habits.

Studieoversikt

Status

Har ikke rekruttert ennå

Forhold

Intervensjon / Behandling

Studietype

Intervensjonell

Registrering (Antatt)

68

Fase

  • Ikke aktuelt

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

45 år til 80 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Voluntary written informed consent signed prior to any study-related procedures.
  • Age between 45 and 80 years (inclusive) at the time of screening.
  • Classified as "metabolically neglected" with documented pre-disease conditions or regulated early-stage chronic disorders.
  • Accelerated biological aging rate 1.1, OR between 1.05 and 1.099 combined with chronic low-grade inflammation (inflammaging).
  • Preserved cognitive function with a Montreal Cognitive Assessment (MoCA) score between 24 and 30 points.
  • Physical ability to perform computerized cognitive tests on a touch-screen tablet.
  • Commitment to maintaining stable dietary and physical activity habits throughout the study period.
  • Possession of a home freezer and ability to strictly comply with cold-chain storage logistics for investigational products and stool samples.
  • Demonstrated ability to swallow large capsules.
  • Adequate baseline laboratory parameters (such as blood counts and kidney function).
  • For women of childbearing potential: agreement to use a highly effective method of contraception throughout the study and for 30 days post-intervention.
  • Readiness to ensure presence at the registered home address to receive scheduled frozen-chain courier shipments.

Exclusion Criteria:

  • Systemic antibiotic therapy within 12 weeks prior to baseline.
  • Supplementation with any commercial pre- or probiotics within 4 weeks prior to baseline.
  • Diagnosed malignancy within the past 5 years (except fully cured basal cell carcinoma or cervical cancer in situ).
  • Participation in any other clinical study or trial within 30 days prior to consent or during this study.
  • Pregnancy, breastfeeding, or planning a pregnancy during the study and for 30 days post-intervention.
  • Known hypersensitivity, intolerance, or allergy to any component of the investigational product (MBiotix HBI Caps), placebo, preparation antibiotics (Neomycin, Metronidazole), antibiotic placebo, or bowel cleansing solution (macrogols).
  • Pre-existing hearing loss, chronic tinnitus, or diagnosed vestibular disorder. History of or active peripheral neuropathy of any etiology.
  • Myasthenia gravis or other neuromuscular transmission disorders.
  • Concurrent, ongoing use of loop diuretics, other aminoglycoside antibiotics, or known nephrotoxic drugs.
  • Severe, unstable, or uncontrolled comorbidities, including NYHA Class III/IV heart failure, unstable angina, or myocardial infarction within the past 6 months.
  • Severe hepatic impairment (Child-Pugh Class C) or severe renal impairment (eGFR < 30 mL/min/1.73 m²).
  • Active, severe psychiatric disorders (e.g., severe depression with active suicidal ideation, psychotic disorders, unstable bipolar disorder).

Diagnosis of progressive neurodegenerative diseases (Parkinson's, Alzheimer's) or moderate-to-advanced dementia.

  • Active, clinically significant inflammatory bowel disease (Crohn's disease, ulcerative colitis) or other severe gastrointestinal disorders.
  • Evidence of gastrointestinal mucosal damage (ulceration, perforation, bleeding) within 7 days prior to the first product dose.
  • Clinically significant immunosuppression, including chronic systemic corticosteroids, HIV infection with a CD4+ cell count < 200/µl, history of solid organ or hematopoietic stem cell transplantation.
  • Active infection requiring antibiotics during the induction phase or anticipated antibiotic use during the first 7 days post-induction.
  • Prior fecal microbiota transplantation (FMT) treatment for indications other than recurrent C. difficile infection.
  • Significant dysphagia precluding safe capsule ingestion.
  • Inadequate baseline laboratory parameters (such as blood counts and kidney function).
  • Any medical condition or circumstance judged by the Principal Investigator to compromise participant safety or protocol adherence.
  • Anticipated inability to comply with study procedures, such as missing scheduled follow-up visits, lacking reliable home freezer storage, or having a lifestyle/occupation that prevents proper cold-chain product handling or consistent attendance.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Firemannsrom

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: MBiotix HBI Caps

MBiotix HBI Caps (FMT capsules) + Preparation antibiotics (Neomycin and Metronidazole) + Standard bowel cleansing (Macrogols). Participants receive targeted preparation antibiotics followed by bowel cleansing, and then a multi-dose regimen of fecal microbiota transplantation (FMT) capsules (MBiotix HBI Caps) in an initial induction phase and subsequent booster cycles.

Fecal microbiota transplantation (FMT) capsules administered in an initial induction phase followed by subsequent booster cycles. Frozen oral capsules containing full-spectrum human gut microbiota given as an initial induction (comprising a single dose on Day 7 and split daily doses on Days 9-14) following preparation, followed by intermittent 6-day booster cycles administered approximately every 4 weeks.

Placebo komparator: Placebo

Placebo Capsules (matching MBiotix HBI Caps) + Antibiotics Placebo (matching two active antibiotics) + Standard bowel cleansing (Macrogols). Participants receive matching placebo treatments for both the preparation antibiotics and the oral capsules (MBiotix HBI placebo), along with the same standard bowel cleansing and multi-dose schedule (an initial induction phase and subsequent booster cycles).

Placebo Capsules (Comparator): Frozen oral capsules identical in appearance, packaging, and dosing schedule to the active product, containing pharmacologically inert substances. Administered as an initial induction phase (single dose on Day 7 and split daily doses on Days 9-14) following preparation, followed by intermittent 6-day booster cycles administered approximately every 4 weeks

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Percentage of Participants Achieving Clinical and Biological Response (Responder Rate)
Tidsramme: Baseline, Week 13, and Week 26

The primary outcome is the proportion of participants categorized as "Responders" following multi-dose fecal microbiota transplantation (MBiotix HBI Caps) compared to placebo. A participant is classified as a Responder if they demonstrate objective physiological improvement from Baseline to Week 13 and/or Week 26, defined as meeting at least one of the following two pre-specified criteria:

  • Epigenetic Deceleration: A reduction of at least 5% from baseline in the DunedinPACE biological pace-of-aging algorithm.
  • Attenuation of Inflammaging: A reduction of at least 25% from baseline in at least one circulating systemic inflammatory marker from the predefined panel (provided the marker was significantly elevated at baseline per study inclusion criteria).

Results will be reported as the percentage of participants in each treatment arm meeting this composite response definition.

Baseline, Week 13, and Week 26

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. desember 2026

Primær fullføring (Antatt)

1. desember 2027

Studiet fullført (Antatt)

1. desember 2027

Datoer for studieregistrering

Først innsendt

23. oktober 2026

Først innsendt som oppfylte QC-kriteriene

30. oktober 2026

Først lagt ut (Faktiske)

3. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

3. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

30. oktober 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • 13/HBI/2026

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .